S-enantiomer pyrrolidinone (SV2A ligand)
The (S)-enantiomer of etiracetam, FDA-approved as Keppra for partial-onset seizures, characterized by the SV2A synaptic vesicle binding mechanism distinct from classical racetam pharmacology.
Abstract
Levetiracetam (Keppra; (S)-ฮฑ-ethyl-2-oxo-1-pyrrolidineacetamide; CAS 102767-28-2; molecular formula C8H14N2O2; molecular weight 170.21) is the (S)-enantiomer of etiracetam, developed at UCB Pharma and approved by the FDA in 1999 for partial-onset seizures, with subsequent expansion to primary generalized tonic-clonic seizures and myoclonic seizures. The compound is distinct from other racetams in mechanism: levetiracetam binds with high affinity (Kd approximately 1 microM) to synaptic vesicle protein 2A (SV2A), a presynaptic vesicle membrane protein involved in neurotransmitter release regulation. SV2A binding modulates calcium-dependent neurotransmitter release and reduces hypersynchronous neuronal firing in epileptic networks. The compound has minimal effect on classical neurotransmitter receptors. Pharmacokinetics: plasma half-life 6 to 8 hours; oral bioavailability essentially complete; renal excretion with minimal hepatic metabolism. The compound is also studied off-label for cognitive enhancement based on hippocampal hyperactivity attenuation, with mixed results in mild cognitive impairment trials. Schedule status varies; the compound is not scheduled federally in the United States but is prescription-only.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.